First confirmed case of nonimmediate hypersensitivity to fremanezumab during chronic migraine treatment

Contact Dermatitis. 2022 Apr;86(4):308-310. doi: 10.1111/cod.14018. Epub 2021 Dec 18.

Authors

Beatriz Moya^{1

2}, Ruth Barranco^{1

2}, Ismael García-Moguel^{1

2}, Mario Puerta-Peña³, Lucía Alonso⁴, Jesús Fernández-Crespo^{1

2}

Affiliations

¹ Department of Allergy, Hospital Universitario 12 de Octubre, Madrid, Spain.
² Instituto de Investigación Sanitaria, Hospital 12 de Octubre (imas12), Madrid, Spain.
³ Department of Dermatology, Hospital Universitario 12 de Octubre, Madrid, Spain.
⁴ Department of Pharmacy, Hospital Universitario 12 de Octubre, Madrid, Spain.

PMID: 34870868
DOI: 10.1111/cod.14018

No abstract available

Keywords: case report; drug hypersensitivity; fremanezumab; injection site reaction; intradermal test; nonimmediate.

Publication types

Case Reports

MeSH terms

Antibodies, Monoclonal
Dermatitis, Allergic Contact*
Drug Hypersensitivity*
Humans
Migraine Disorders* / drug therapy

Substances

Antibodies, Monoclonal
fremanezumab